Insight

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer – ESMO Open

ESMO Open/X

May 30, 2025, 00:26

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer – ESMO Open

ESMO Open shared a post on X:

“Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer in ESMO Open. 101 patients with solid tumors, ORR 77%, mDOR and mPFS 59 and 61 months, respectively. 88% of patients with TRAES, 26% of G3 or higher.”

Title: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

Authors: D.S. Hong, R.-H. Xu, L. Shen, M.P. Dierselhuis, D. Orbach, R. McDermott, A. Italiano, M. Tahara, V. Bernard-Gauthier, N. Neu, C.E. Mussi, E. De La Cuesta, T.W. Laetsch, A. Drilon

Read the Full Article.

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer - ESMO Open

A. Drilon A. Italiano C.E. Mussi cancer D. Orbach D.S. Hong E. De La Cuesta ESMO Open L. Shen M. Tahara M.P. Dierselhuis N. Neu OncoDaily Oncology R. McDermott R.-H. Xu T.W. Laetsch V. Bernard-Gauthier

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Robin Zon: The Official End of My Term as ASCO President